Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions
- Institution
- H. LEE MOFFITT CANCER CTR & RES INST, FL
- Principal investigator
- Katarzyna Anna Rejniak
- Funding
- $1.2M
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group of neoplastic lesions confined to the mammary ducts. Reactive stroma emerges during early breast cancer development and co-evolves with breast cancer progression. While genetic alterations during breast carcinogenesis have been extensively studied, more in-depth investigation is needed into the non-genetic microenvironmental factors that select for these genotypes. We hypothesize that emergence of reactive stroma precedes initiation of microinvasion, and that this process is an effect of a modified tissue metabolic landscape. This hypothesis will be tested using the interdisciplinary approach by explicitly integrating experimental and computational models that together are able to handle this problem complexity. We have assembled a multidisciplinary team of investigators to quantify tumor cell-stroma interactions under different metabolic conditions (aim 1); assess the role of reactive stroma in DCIS upgrading (aim 2); and evaluate reactive stroma signatures in DCIS histology (aim 3). We will pursue these aims by using a comprehensive approach that combines studies of DCIS histology samples, three-dimensional (3D) tumor organoid cultures, mathematical modeling of complex tumor microenvironment, and quantitative algorithms applied to medical imaging. Our goal is to define novel molecular and physical signatures of reactive stoma with a goal to improve preventive and therapeutic strategies.
Research team
- Mehdi DamaghiPI
- Katarzyna Anna RejniakPI
LOADING MOONBASE SCORE
Questions for H. LEE MOFFITT CANCER CTR & RES INST
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · H. Lee Moffitt Cancer Ctr & Res InstNot yet scored
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
Shari Pilon-Thomas · $476K · 2021–2026
- NIH · H. Lee Moffitt Cancer Ctr & Res InstNot yet scored
Radiomics and Pathomics to predict upstaging of DCIS
Mehdi Damaghi · $683K · 2021–2026
- NIH · H. Lee Moffitt Cancer Ctr & Res InstNot yet scored
The oncogenic roles of alarmins and monocytes in triple negative myelofibrosis
Nicole Vincelette · $157K · 2025–2028